Literature DB >> 20674189

Importance of DNA damage checkpoints in the pathogenesis of human cancers.

Angela Poehlmann1, Albert Roessner.   

Abstract

All forms of life on earth must cope with constant exposure to DNA-damaging agents that may promote cancer development. As a biological barrier, known as DNA damage response (DDR), cells are provided with both DNA repair mechanisms and highly conserved cell cycle checkpoints. The latter are responsible for the control of cell cycle phase progression with ATM, ATR, Chk1, and Chk2 as the main signaling molecules, thus dealing with both endogenous and exogenous sources of DNA damage. As cell cycle checkpoint and also DNA repair genes, such as BRCA1 and BRCA2, are frequently mutated, we here discuss their fundamental roles in the pathogenesis of human cancers. Importantly, as current evidence also suggests a role of MAPK's (mitogen activated protein kinases) in cell cycle checkpoint control, we describe in this review both the ATR/ATM-Chk1/Chk2 signaling pathways as well as the regulation of cell cycle checkpoints by MAPK's as molecular mechanisms in DDR, and how their dysfunction is related to cancer development. Moreover, since damage to DNA might be the common underlying mechanism for the positive outcome of chemotherapy, we also discuss targeting anticancer treatments on cell cycle checkpoints as an important issue emerging in drug discovery. Copyright 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20674189     DOI: 10.1016/j.prp.2010.06.006

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  29 in total

1.  Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Authors:  George T Lountos; Andrew G Jobson; Joseph E Tropea; Christopher R Self; Guangtao Zhang; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  J Struct Biol       Date:  2011-09-22       Impact factor: 2.867

2.  DNA damage response and its clinicopathological relationship in appendiceal tumors.

Authors:  Nobuhisa Yajima; Ryuichi Wada; Yutaka Matsuzaki; Soroku Yagihashi
Journal:  Int J Colorectal Dis       Date:  2014-08-26       Impact factor: 2.571

3.  Characterization of LGALS3 (galectin-3) as a player in DNA damage response.

Authors:  Renato S Carvalho; Vanessa C Fernandes; Thales C Nepomuceno; Deivid C Rodrigues; Nicholas T Woods; Guilherme Suarez-Kurtz; Roger Chammas; Alvaro N Monteiro; Marcelo A Carvalho
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

4.  Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy.

Authors:  Chang Gong; Bodu Liu; Yandan Yao; Shaohua Qu; Wei Luo; Weige Tan; Qiang Liu; Herui Yao; Lee Zou; Fengxi Su; Erwei Song
Journal:  J Biol Chem       Date:  2015-04-20       Impact factor: 5.157

5.  Astroglial U87 Cells Protect Neuronal SH-SY5Y Cells from Indirect Effect of Radiation by Reducing DNA Damage and Inhibiting Fas Mediated Apoptotic Pathway in Coculture System.

Authors:  Yasmeen Saeed; Abdul Rehman; Bingjie Xie; Jin Xu; Ma Hong; Qing Hong; Yulin Deng
Journal:  Neurochem Res       Date:  2015-07-05       Impact factor: 3.996

Review 6.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

7.  TIMP3 controls cell fate to confer hepatocellular carcinoma resistance.

Authors:  V Defamie; O Sanchez; A Murthy; R Khokha
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

8.  Germline mutation in ATR in autosomal- dominant oropharyngeal cancer syndrome.

Authors:  Akio Tanaka; Sarah Weinel; Nikoletta Nagy; Mark O'Driscoll; Joey E Lai-Cheong; Carol L Kulp-Shorten; Alfred Knable; Gillian Carpenter; Sheila A Fisher; Makiko Hiragun; Yuhki Yanase; Michihiro Hide; Jeffrey Callen; John A McGrath
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

9.  Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer.

Authors:  Jikai Yin; Charles Lu; Jian Gu; Scott M Lippman; Michelle A T Hildebrandt; Jie Lin; David Stewart; Margaret R Spitz; Xifeng Wu
Journal:  Carcinogenesis       Date:  2011-09-28       Impact factor: 4.944

Review 10.  X-ray repair cross-complementing group 1 polymorphisms and hepatocellular carcinoma: a meta-analysis.

Authors:  Tian Xie; Zhen-Guang Wang; Jing-Lei Zhang; Hui Liu
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.